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Abstract
Background: Colorectal Cancers (CRC) are one of the most common malignancies in the world. Their incidence in
Morocco, between 2005 and 2007, was 5.6 for 100000 inhabitants, which is very low compared to what found in
developed countries. In addition, CRCs show a high frequency of rectal localizations, and occurs in a younger
population in Morocco compared to what found in developed countries.
The purpose of this study is to confirm these CRC peculiarities in Morocco and try to explain them by exploring the
microsatellite instability molecular pathway.
Methods: This is a prospective observational study conducted since January 2010, including 385 patients admitted
in Hassan II University Hospital of Fez. We collected clinical, radiological and pathological data. We investigated the
expression of mismatch repair (MMR) proteins in 214 patients and BRAF gene mutations in 159 patients.
Results: Mean age was 55.08 +/− 15.16 years. 36.5 % of patients were less than 50 years old and 49.3 % of tumors
were localized in the rectum. Loss of MMR protein expression was observed in 11.2 % of cases. It was independently
associated with individual or family history of cancer belonging to Hereditary Non-Polyposis Colorectal Cancer (HNPCC)
spectrum (p = 0.01) and proximal localization (p = 0.02). No BRAF mutation was detected in all cases.
Conclusions: These results confirm the high occurrence of CRCs to young patients and the high frequency of rectal
localizations in Moroccan population. They mostly show an absence of BRAF mutation, supposing a rarity of MLH1
promoter hypermethylation pathway, which may even partially explain the CRC peculiarities in our context.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
5868184711716884
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Background
Colorectal cancers (CRC) are one of the most common
malignancies representing the third most common can-
cer for men and the second for women in the world [1].
Their incidence in Morocco, between 2005 and 2007,
was 5.6 for 100000 inhabitants [2]. Several previous epi-
demiological studies demonstrated that the CRC
incidence in Morocco is similar to that in neighboring
Maghreb countries but very low compared to what
found in developed countries [3] (Table 1). In addition,
CRCs show a high frequency of rectal localizations and
occur more to a younger population compared to what
found in developed countries [2, 4]. According to the
Casablanca Moroccan Region Cancer Registry, the rectal
cancer mean age occurrence is 58.1 years for men and
54.2 years for women; and the colon cancer mean age
occurrence is 56.8 years for men and 57.2 years for
women [2].
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CRC develop through a multistep carcinogenic process
with an accumulation of epigenetic and genetic changes.
So for the same histology, the underlying molecular ab-
normalities can be very different and could explain the
wide variation in clinical course and responses to therap-
ies for different patients. Several molecular mechanisms
are implicated in CRC carcinogenesis: Chromosomal In-
stability (CIN), MicroSatellite Instability (MSI) and the
CpG Island Methylator Phenotype (CIMP) [5].
CIN pathway is found in about 85 % of sporadic CRC
and in familial adenomatous polyposis. It is character-
ized by loss or gain of chromosome arms, chromosomal
translocations or gene amplifications [6]. This ‘traditional
pathway’ is the most well characterized which involves the
progression of a conventional type adenoma that may ac-
quire mutation or loss of APC, mutation of KRAS and
TP53, and chromosomal instability before the occurrence
of an invasive adenocarcinoma [7].
MSI pathway is found in approximately 15 % of
sporadic CRC and 95 % of Hereditary Non-Polyposis
Colorectal Cancer (HNPCC) syndrome [8, 9]. Microsa-
tellites are short repetitive DNA sequences found
throughout the tumor genome that are prone to muta-
tions [10]. MSI occurs in the case of DNA mismatch
repair (MMR) genes inactivation (MLH1, MSH2, MSH6
or PMS2) secondary to germline or somatic mutations.
MMR deficiency leads to DNA replication errors within
microsatellites [11].
Two sub-types of CRC MSI-high have been described:
– One resulting from Germline MMR mutations
associated to HNPCC Syndrome, an autosomal
dominant disorder that accounts for ~3 % of all
CRC [12].
– The other from a somatic epigenetic event in the
promoter of a single DNA mismatch repair gene
(MLH1) [12]. The later subset is known as sporadic
MSI-H colorectal cancer and is also characterized by
extensive methylation of multiple gene promoter
regions called the CpG island methylator phenotype
(CIMP). Approximately 20 % of CRCs are CIMP-high
tumors and are thought to arise from serrated polyps
[13]. Sporadic MSI-H colorectal cancers frequently
exhibit hotspot mutations in the BRAF oncogene [14].
BRAF encodes a serine/threonine kinase that is an
essential component of the RAF/MEK/ERK/MAPK
signaling cascade which promotes cellular proliferation
and anti-apoptotic effects. In CRC, BRAF mutations
are located in a hotspot in exon 15 that leads to a
V600E single-amino-acid substitution [15]. BRAF
mutation is considered a marker for the serrated
pathway and is found in approximately 10–15 % of
CRC, including the majority of those showing CIMP
[16]. It is associated withMLH1 promoter methylation,
indicates a sporadic MSI CRC and essentially excludes
a diagnosis of HNPCC (Lynch) syndrome [15, 17, 18].
The aim of this study is to confirm the CRC peculiarities
in Moroccan population. Then, to explore the micro satel-
lite instability molecular pathway with the hypotheses,
which it could explain these CRC peculiarities, particularly
the differences in incidence between Morocco and devel-
oped countries.
Methods
This is a prospective observational study conducted
since January 2010, including 385 patients with CRC,
admitted in Hassan II University Hospital of Fez.
Ethics statements
Written, informed consent was obtained from each pa-
tient involved in this observational study. This research
was approved by Hassan II University Hospital Ethics
Committee.
Study Population and Histological Features
We collected clinical and endoscopic data (age, sex,
personal and family history and tumor localization),
radiological data (extension to adjacent organs, visceral
metastasis), and pathological data (Histologic type and
differentiation, local invasion, lymph node metastasis,
peritoneal carcinomatosis…). Classification of CRC was
done according to 2010 World Health Organization
criteria for histological type, differentiation and tumor
stage.
Expression of DNA Mismatch Repair Proteins
Immunohistochemical analysis of DNA mismatch repair
proteins MLH1 and MSH2 was performed on Ventana
Benchmark Ultra automaton in 214 tumor samples. To
increase the sensitivity of immunohistochemistry, we
also studied the expression of MSH6 and PMS2 by the
same technique [12, 19].
Four μm tissue sections from formalin-fixed paraffin-
embedded tissue were stained with antibodies against
hMLH1 (clone G168-728; Cell marque), hMSH2 (clone
G219-1129; Cell Marque), hMSH6 (clone BC/44; Cell
Marque), and PMS2 (clone MRQ-28; Cell Marque).
Absence of nuclear staining in tumor cells with the
presence of positive staining in surrounding cells
Table 1 Comparison of estimated CRC incidence rate (for
100,000 inhabitants) in Morocco with that in other countries in
2012 [3]
Morocco Tunisia USA Canada France
Men 9 - 16.1 9 - 16.1 16.1 - 32.2 >32.2 >32.2
Women <4.5 4.5 - 7.6 >21.8 >21.8 >21.8
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(lymphocytes or normal glandular cells) was inter-
preted as a loss of expression of these proteins.
DNA isolation
One representative tissue section and the corresponding
paraffin block were selected. The tumor area was
marked on the Hematoxylin eosin-stained slide. The
percentage of tumor cells in the marked area and the
relative amounts of different histoanatomical compo-
nents of the tumor were estimated to guarantee a valid
tumor cell content. DNA was then extracted from
formalin-fixed, paraffin-embedded tissue with the
QIAamp DNA mini kit (Qiagen®, Hilden, Germany)
following the manufacturer’s instructions. Moreover,
the isolated DNA quality and amplified products were
determined by optical density (OD260/280) measure-
ments (Nanoview®).
Microsatellite Instability Assay
Microsatellite instability (MSI) was assessed in 7 tumor
samples with loss of expression of MMR proteins by the
Molecular Pathology laboratory in Bergonie Institute,
Bordeaux (France), using a fluorescent multiplex PCR-
based method with a set of five mononucleotide markers
(BAT25, BAT26, NR21, NR22, NR24). Polymerase chain
reaction (PCR) for the various microsatellite markers
was carried out only on tumor DNA. Standard PCR con-
ditions were used. Primers were custom ordered with
various fluorescent dyes from life technologies®. The
analysis of variability in the length of PCR product cor-
responding to the microsatellite markers was performed
on ABI 3100 (life technologies®). Tumors were classified
as MSI-high if >2 of the 5 markers are unstable; micro-
satellite stable (MSS) when there is an absence of in-
stability and MSI-low if only 1 marker is unstable. This
latter is considered as a MSS status.
Detection of BRAF Mutations
Mutant allele-specific PCR
Tumor DNA was analyzed in 159 CRC to detect the
V600E point mutation in exon 15 of the BRAF gene by
the use of an allele–specific PCR using mutation-specific
primers. This PCR was performed in a final volume of
50 μl containing 2 μl of forward primer: 5’-GGTG
ATTTTGGTCTAGCTACATA-3’, tow μl of reverse
primer 5’-GGCCAAAAATTTAATCAGTGGA-3’ (12.5
μMl), 0.4 μl of Taq polymerase Platinium®, 5 μl of Mix
10X Buffer (Invitrogen®), 1 μl of dNTPs (10 mM), 2 μl of
MgCl2 (50 mM), 32.6 μl of free DNA/RNA water and
50 ng of DNA. Then, an agarose gel electrophoresis was
performed for the resulting PCR products with a positive
control containing the BRAF V600E mutation.
PCR- direct sequencing
In addition, for all tumors with loss of expression of
MMR proteins, and 6 tumors with conservation of ex-
pression of MMR proteins, the result of the BRAF allele-
specific PCR was confirmed by screening of BRAF (exon
15) using direct sequencing of PCR products in forward
and reverse. PCR products generated using the following
primer pairs: forward 5’-TGCTTGCTCTGATAGGA
AAATG-3’ and reverse 5’-GTAACTCAGCAGCATCTC
AGGG-3’. This PCR was performed in a final volume of
50 μl, containing 0.4 μl of Taq polymerase Platinium®,
5 μl of Mix 10X Buffer (Invitrogen®), 1 μl of dNTPs
(10 mM), 2 μl of forward and reverse primers (12.5 μM),
2 μl of MgCl2 (50 mM), 32.6 μl of free DNA/RNA
water, and 50 ng of DNA. Thermocycling was per-
formed at 95 °C for 10 min, followed by 35 cycles of
95 °C for 30 s, 60 °C for 60 s and 72 °C for 30 s,
and one last cycle of 72 °C for 10 min. The resulting
PCR products were purified, and tested for the pres-
ence of mutations by bi-directional Sanger sequencing
on the 3500 Genetic Analyzer (Applied Biosystems®)
using the original PCR primers and the BigDye®
Terminator V1.1 Cycle Sequencing Kit (Life technolo-
gies, Foster City, CA, USA), according to the manu-
facturer’s recommendations.
These tests are ongoing for the remaining patients.
Statistics analysis
The data were analyzed on the software EPI Info version
3.4.
- Firstly, we studied all independent variables distri-
bution of: age, sex, personal or family history of cancer
belonging to HNPCC spectrum, histological and im-
munohistochemical parameters.
- In second time, we compared patients with preserved
MMR proteins and patients with loss of MMR protein
expression using the chi-square test and Fisher’s exact




Clinical and radiological features
Mean age was 55.08 +/− 15.16 years. 36.5 % of patients
were less than 50 years old. Sex ratio M/F = 1.05.
10.1 % of patients had an individual or family his-
tory of cancer belonging to HNPCC spectrum. At
diagnosis, the average tumor size was 5.8 +/−
2.5 cm. 49.3 % of tumors were located in the rec-
tum, while the proximal locations accounted for only
19.4 %.
26.3 % of patients presented with one or several vis-
ceral metastasis. Secondary localizations were mainly
liver, lung and ovary (Fig. 1).
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Pathological features
Adenocarcinoma was the most common histological
type found in 88.1 % of cases. 92.5 % of tumors are well
or moderately differentiated. Mucinous component and
Independent cells component are found in 16.1 % and
6 % of tumors respectively.
pT3 Stage was the most common found in 78.4 % of
cases. Synchronous CRC were present in 3.9 % of cases.
Extension to adjacent organs, lymph metastasis and peri-
toneal carcinomatosis were found respectively at 13.9 %,
29.6 % and 15.6 % of patients (Details in Table 2).
Loss of MMR protein expression was observed in
11.2 % of cases. It is dominated by the simultaneous loss
of MLH1 and PMS2 proteins which represents 2/3 of
cases with MMR protein loss (Figs. 2 and 3). Table 3
shows the principal clinical and pathological features of
patients with loss of expression of MMR proteins.
Molecular analysis
Microsatellite instability was confirmed in 7 tumor sam-
ples using microsatellite instability assay (Fig. 4).
V600E BRAF mutation detection was performed on
159 cases, and did not find any mutation (Figs. 5 and 6).
This test is in progress for the remaining cases.
Data have been deposited in Cosmic database. Acces-
sion Numbers: (unique id_study, 605).
Analytical study
Univariate analysis demonstrated significant association
between loss of MMR proteins with the presence of
Individual or family history of cancer belonging to
HNPCC spectrum (p = 0.001), Lymph node metastasis
(p = 0.02), synchronous colorectal cancer (p = 0.0003)
and proximal localization (p = 0.00001). Associations
with histologic type, tumor stroma and the presence of
visceral metastasis were not statistically significant.
However, in multivariate analysis, only individual or
family history of cancer belonging to HNPCC spectrum
(p = 0.01, Odds ratio = 35.8 [95 % CI 2.2- 588]); and
proximal location (p = 0.02, Odds ratio = 21 [95 % CI
1.4-316.3]) were confirmed to be associated with loss of
expression of MMR proteins (Details in Table 4).
Discussion
The frequency of MLH1 promoter methylation in spor-
adic CRC varied from 0.0 % [20] to 66.9 % [21]. In one
Meta-analysis including 5584 patients, the frequency of
MLH1 promoter methylation in unselected CRC was
20.3 % [22]. These cancers with MLH1 methylation are
more commonly observed within older females. It may
be due to estrogen decrease with age and could explain
why the MSI-H status is more common for women [23].
In our study, we didn’t find any case of CRC with both
MMR proteins expression loss and BRAF mutation. This
result confirms an earlier study led in Hassan II Univer-
sity Hospital of Fez, which took 62 samples of patients
with sporadic colorectal adenocarcinomas brought in
our pathology laboratory before 2010. So, only one pa-
tient (1.6 %) carried BRAF codon 600 mutation [24], that
is lower than what found in literature, were BRAF muta-
tions are found out in approximately 10–15 % of CRC.
In Tunisia, where population is similar to Morocco, one
study, including 51 patients with CRC, found out also
just one patient with a BRAF somatic mutation and this
tumor has a MSS status [25]. Further analysis of MLH1



















Fig. 1 Distribution of metastatic sites at diagnosis
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showing MSI-H phenotype and MLH1 protein expres-
sion loss with absence of MLH1 deleterious somatic
mutation by Multiplex Ligation-dependent Probe Ampli-
fication (MLPA) or sequencing, did not detect aberrant
methylation discarding the hypothesis of sporadic can-
cers due to epigenetic inactivation of MLH1 gene [25].
Another element that reinforces our results is the rarity
of serrated lesions in our context. In an earlier study
conducted in our laboratory between 2004 and 2007, we
did not find any serrated adenoma among 86 colorectal
polyps [26]. On the other hand, the MMR protein
Table 2 Clinicopathological and Immunohistochemical
Characteristics in CRCs. Fez, Morocco, 2010-2013
Characteristics Frequencies
(%)
Gender (n = 385) Male 51.4
Female 48.6
Age rang (n = 385) <50 years 36.5
>50 years 63.5
Individual or family history of
cancer belonging to HNPCC
spectrum (n = 208)
Yes 10.1
No 89.9



























































Table 2 Clinicopathological and Immunohistochemical
Characteristics in CRCs. Fez, Morocco, 2010-2013 (Continued)








aspect of extension to adjacent
organs (n = 303)
Yes 13.9
No 86.1
Visceral metastasis (n = 285) Yes 26.3
No 73.7
Peritoneal carcinomatosis (n = 288) Yes 15.6
No 84.4
Stage M (n = 285) 0 65.6
1a 14.4
1b 20




MMR proteins not expressed
(n = 24)
MLH1 and PMS2 66.7
MSH2 and MSH6 33.3
Fig. 2 Immunohistochemical study of a colonic adenocarcinoma
using anti-MSH2 antibodies (Grossissment x200): Conservation of
MSH2 expression both in normal mucosa and carcinoma cells
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expression loss was independently associated in this
study with personal or family history of cancer belonging
to HNPCC spectrum. This is another index for the high
rate of HNPCC syndrome. One study on MLH1 and
MLH2 germline mutations is in progress in our
laboratory.
MSI-H phenotype is associated with proximal tumor
location, poor differentiation and/or mucinous histology,
dense lymphocyte infiltration and low frequency of
lymph node and distant organ metastasis [10]. In our
study, CRCs with MMR protein loss were associated
with proximal tumor location. We also found that
49.3 % of CRC are located in the rectum. This confirms
data of The Casablanca Moroccan Region Cancer Regis-
try which show that 43.2 % of CRC are located in the
rectum [2]. This is a further demonstration of the rela-
tive increase in rectal locations for Moroccan population
which is very high compared to what is observed in
Europe, where it varies between 20 and 35 % [27].
In contrast to colon cancer, rectal cancer missed
V600E BRAF mutations [28]. Gaedcke and al detected
no V600E BRAF mutations in 94 rectal cancer patients
Fig. 3 Immunohistochemical study of a colonic adenocarcinoma
using anti-MLH1 antibodies (Grossissment x400): Loss of MLH1
expression in tumor cells (Internal control positive)
Table 3 Principal clinical and pathological features of patients with MMR proteins loss. Fez, Morocco, 2010-2013
Cases Age Gender Localization Histologic type Histologic Differenciation Stage pT Stage pN Stage M Lost proteins
1 45 Male Right colon Adenocarcinoma well 2 0 0 MLH1/PMS2
2 45 Male Right colon Mucinous Carcinoma well 3 0 0 MSH2/MSH6
3 49 Male Rectum Adenocarcinoma well x x 1a MLH1/PMS2
4 80 Female Right colon Adenocarcinoma average 3 0 1a MLH1/PMS2
5 54 Male Left colon Mucinous Carcinoma average 3 0 x MSH2/MSH6
6 64 Female Right colon Adenocarcinoma well 3 0 0 MLH1/PMS2
7 38 Male Right colon Adenocarcinoma well 3 0 x MLH1/PMS2
8 61 Male Right colon Adenocarcinoma well 3 1a x MLH1/PMS2
9 41 Male Left colon Adenocarcinoma well x x 1b MSH2/MSH6
10 55 Male Right colon Adenocarcinoma poor 3 0 x MSH2/MSH6
11 48 Male Right colon Adenocarcinoma poor 4a 0 1b MSH2/MSH6
12 31 Male Rectum Adenocarcinoma average x x 1a MLH1/PMS2
13 71 Male Left colon Adenocarcinoma average 3 2a 1a MLH1/PMS2
14 70 Male Rectum Adenocarcinoma well 3 2a x MLH1/PMS2
15 81 Male Right colon Adenocarcinoma poor 3 0 x MLH1/PMS2
16 50 Female Left colon Adenocarcinoma average x x 1a MLH1/PMS2
17 56 Female Right colon Adenocarcinoma average 4b 0 1b MLH1/PMS2
18 50 Female Right colon Adenocarcinoma average 3 0 1b MLH1/PMS2
19 28 Male Right colon Adenocarcinoma poor 3 0 0 MLH1/PMS2
20 53 Male Right colon Adenocarcinoma well 3 0 0 MSH2/MSH6
21 74 Male Left colon Adenocarcinoma average 3 0 0 MLH1/PMS2
22 53 Male Right colon Adenocarcinoma well 3 0 0 MSH2/MSH6
23 70 Male Not specified Adenocarcinoma well x x x MSH2/MSH6
24 56 Male Left colon Adenocarcinoma well 4b 0 0 MLH1/PMS2
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suggesting that BRAF mutations [28] and consequently
MLH1 gene promoter hypermethylation [15, 17, 18] do
not seem to play any role in rectal cancer pathogenesis.
The rarity of MLH1 gene promoter hypermethylation
pathway in Moroccan context could explain the rela-
tive high frequency of rectal locations which is in fact
caused by a reduction in the number of patients with
right location. This would also contribute partially to
an overall decrease in the number of CRCs in our con-
text and therefore explain the relative low incidence of
CRC.
MLH1 Promoter hypermethylation is not an isolated
process, but part of an overall epigenetic DNA methyla-
tion process. For example, in other studies, sporadic
MSI tumors were associated with higher rates of hyper-
methylation of the PTEN tumor suppressor gene com-
pared to MSS tumors [29]. To explain the probable
rarity of MLH1 promoter hyper methylation in our re-
gional context, we suggest several hypotheses:
1- Some reports noticed that DNA methylation process
may be influenced by genetic factors. Genetic
variants polymorphisms at a specific locus can
influence both regional and distant DNA methylation
[30]. Twin and family-based studies suggest that a
significant proportion of inter-individual variability
in DNA methylation is determined genetically [31].
Relatives of CRC cases with MLH1 methylation
present increased risk of colorectal, stomach and
ovarian cancer, suggesting that there may be a heritable
factor for CRC and other cancers associated with
MLH1 methylation in non-HNPCC Syndrome CRC
[32]. The rarity of hypermethylation in Tunisian
patients with CRC [25] could be related to genetic
variants. This could also be present within Moroccan
population who’s ethnically similar and geographically
close to the Tunisian population; and explain the
observed absence of BRAF somatic mutations.
2- Age is an important risk factor in the development
of colorectal cancers [33]. The cause of age-related
aberrant methylation is not known. It is possible that
upregulation of the de novo methyltransferase DNMT3b
could be responsible for the hypermethylation seen in
aging [34]. Approximately half of genes which can be
involved in age-related methylation are also involved
in the pathogenesis of colon cancer, suggesting a role
for these genes in the increased cancer susceptibility
associated to age [35]. Moroccan population is
relatively young compared to developed countries.
For example, in 2010, the elderly of more than
60 years was 8.4 % in Morocco [36], against 20.9 %
in France [37]. In addition, in 2011, life expectancy
at birth in Morocco was 72 years, against 82 years
Fig. 4 DNA fragment length analysis showing a profile MSI-H: supernumerary peak at 3/5 markers
Fig. 5 Gel electrophoresis of PCR products of allele specific BRAF
showing an absence of V600E mutation
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in France and Canada [38]. The relatively low life
expectancy in our context may explain the rarity of
age related MLH1 promoter hyper methylation
pathway. Youth of our population could also explain
the high proportion of young patients, less than
50 years, which is 36.5 % against 6 % in Europe [27].
3- Epigenetic drift might be due to the accumulation of
small errors in copying DNA methylation marks
during successive cell divisions [39]. It has been
observed that older monozygotic twin pairs
demonstrate greater DNA methylation differences
than younger monozygotic twin pairs [40]. The
differences between twins were greater for pairs that
spent less of their lifetime together or exhibited
more different lifestyles suggesting that environmental
factors play a role in epigenetic drift [40]. Some
carcinogens and environmental factors have been
implicated:
a- Cigarette smoke is considered one of the most
powerful environmental modifiers of DNA
methylation [41]. In a prospective study (n = 37399),
cigarette smoking was associated with BRAF
mutation-positive CRC subtype with a positive
dose–response relationship indicating epigenetic
modification, which may be functionally involved in
smoking-related colorectal carcinogenesis [42].
Carcinogens in cigarette smoke, such as arsenic,
chromium, formaldehyde, polycyclic aromatic
hydrocarbons, and nitrosamines, can damage DNA
by causing double-stranded breaks. Survivor cells
display a high capacity for DNA repair. But, the
DNA repair sites recruit DNMT1, which methylates
CpGs adjacent to the repaired nucleotides [43, 44].
Smoking prevalence is relatively lower in Morocco
compared to developed countries. For example, in
2009, the prevalence of smoking among patients
over 15 years in Morocco was 33 % for men and 2 %
for women, while this prevalence was 36 % for men
and 27 % for women in France [38]. This could also
explain the rarity of MLH1 promoter hyper
methylation pathway in our context.
b- Alcohol is considered one of the factors associated
with DNA methylation. Alcohol may induce aberrant
DNA methylation patterns alterations; these generally
are associated with modulation of the pathways that
regulate the availability of S-adenosylmethionine [45].
Fig. 6 Case Sanger sequencing: no mutation of BRAF forward strand
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Indeed, in chronic alcoholics, serum folate levels
are significantly reduced compared with healthy
subjects. Folic acid deficiency reduces the enzyme
S-adenosylmethionine levels [46]. In addition,
people with low folate intake/high alcohol intake
show a higher frequency of promoter methylation
of genes involved in CRC carcinogenesis (e.g.,
APC-1A, p14ARF, p16INK4a, hMLH1, O6-MGMT,
and RASSF1A) compared with people with high folate
intake/low alcohol intake [47]. One meta-analysis
including 27 cohort and 34 case–control studies
showed a 21 % increased risk of CRC, for moderate
drinkers and 52 % increased risk of CRC for heavy
drinkers (4 drinks/day) with a dose–risk relationship
[48]. Alcoholism prevalence is very lower in Morocco
compared to developed countries. For example, in
2008, the prevalence of alcoholism in patients over
15 years was 1.2 % in Morocco, against 12.5 % in
France [38]. This could also explain the rarity of
MLH1 promoter hyper methylation pathway in our
context.
c- Diet has been described as an important factor in
colorectal carcinogenesis. Several studies have shown
that the highest adherence to Mediterranean diet
resulted in a significantly risk reduction for CRC
[49, 50]. In a Moroccan cross-sectional survey, 70.1 %
of the sample (n = 2214) has a highest adherence to
Mediterranean diet [51]. However, a study of this diet
impact on CRC associated with MLH1 promoter
hypermethylation should be considered to confirm
this hypothesis.
Advances in our understanding of colorectal cancer
molecular pathology has led to the identification of
promising early detection molecular markers for use in
non-invasive colorectal cancer screening assays. At this
time, stool-based methylated VIMENTIN (mVim) is a
clinically validated marker for early colorectal cancers
detection which is now available in the United States
under the name ColoGuard assay (LabCorp®) [52]. In
addition, in Europe, there is a blood-based assay that
detects methylated SEPT9 which is being marketed as a
colon cancer screening assay under the name Epi proCo-
lon (Epigenomics AG®) [52]. However, the rarity of
CIMP-high CRC could make these screening methods,
inadequate in our context.
Conclusions
In Morocco, the rarity of BRAF mutation was confirmed
in our study that found no cases of CRC with this mu-
tation. MMR proteins expression loss was statistically
associated with the presence of Individual or family















Means Age (years) 55.1 56.4 0.7
Age rang < 50 years 8/24 60/190 0.48
Presence of individual or family history of cancer
belonging to HNPCC spectrum
4/9 9/190 0.001 0.01 35.8 [95 % CI 2.2- 588]
Well or moderately differentiated adenocarcinoma 15/24 145/190 0.07
Presence of independent cells component 2/24 13/190 0.52
Presence of mucinous component 5/24 33/190 0.43
Presence of perineural invasion 1/19 12/139 0.51
Presence of vascular embolus 4/19 21/139 0.35
Presence of lymph node metastasis 3/19 53/138 0.02
Presence of synchronous colorectal cancer 6/23 5/185 0.0003
Presence of radiological or/and pathological
extension to adjacent organs
4/21 16/147 0.22
Presence of visceral metastasis 6/17 31/132 0.21
Presence of peritoneal carcinomatosis 4/20 21/146 0.35
Location - - 0.00001 0.02 21 [95 % CI 1.4-316.3]
Right colon 14/23 31/184 - -
Left colon 6/23 64/184 - -
Rectum 3/23 89/184 - -
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history of cancer belonging to HNPCC spectrum.
These two elements suppose a rarity of MLH1 pro-
moter hypermethylation, likely involved in carcinogen-
esis of CRC. Further studies are needed to confirm this
data which partly explain some peculiarities of this
pathology in Morocco, such as the relative high fre-
quency of rectal localizations and low incidence. The
relative youth of Moroccan population could also ex-
plain the high rate of young patients with CRC.
This rarity of MLH1 promoter hypermethylation
pathway in Moroccan population could be explained by
the relative low life expectancy or/and the relative low
prevalence of smoking and alcoholism or/and the high-
est adherence to Mediterranean diet.
Lastly, in Morocco and other third world countries,
given the adoption in the future of a modern lifestyle
and the increase of life expectancy who participate in
DNA hypermethylation damage, we consequently expect
the continuation of the upward trend in the incidence of
this scourge.
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